Cargando…

CB2 Receptor Involvement in the Treatment of Substance Use Disorders

The pharmacological modulation of the cannabinoid receptor 2 (CB2r) has emerged as a promising potential therapeutic option in addiction. The purpose of this review was to determine the functional involvement of CB2r in the effects produced by drugs of abuse at the central nervous system (CNS) level...

Descripción completa

Detalles Bibliográficos
Autores principales: Navarrete, Francisco, García-Gutiérrez, María S., Gasparyan, Ani, Navarro, Daniela, Manzanares, Jorge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8615453/
https://www.ncbi.nlm.nih.gov/pubmed/34827554
http://dx.doi.org/10.3390/biom11111556
_version_ 1784604108522520576
author Navarrete, Francisco
García-Gutiérrez, María S.
Gasparyan, Ani
Navarro, Daniela
Manzanares, Jorge
author_facet Navarrete, Francisco
García-Gutiérrez, María S.
Gasparyan, Ani
Navarro, Daniela
Manzanares, Jorge
author_sort Navarrete, Francisco
collection PubMed
description The pharmacological modulation of the cannabinoid receptor 2 (CB2r) has emerged as a promising potential therapeutic option in addiction. The purpose of this review was to determine the functional involvement of CB2r in the effects produced by drugs of abuse at the central nervous system (CNS) level by assessing evidence from preclinical and clinical studies. In rodents, several reports suggest the functional involvement of CB2r in the effects produced by drugs of abuse such as alcohol, cocaine, or nicotine. In addition, the discovery of CB2r in brain areas that are part of the reward system supports the relevance of CB2r in the field of addiction. Interestingly, animal studies support that the CB2r regulates anxiety and depression behavioral traits. Due to its frequent comorbidity with neuropsychiatric disorders, these pharmacological actions may be of great interest in managing SUD. Preliminary clinical trials are focused on exploring the therapeutic potential of modulating CB2r in treating addictive disorders. These promising results support the development of new pharmacological tools regulating the CB2r that may help to increase the therapeutic success in the management of SUD.
format Online
Article
Text
id pubmed-8615453
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86154532021-11-26 CB2 Receptor Involvement in the Treatment of Substance Use Disorders Navarrete, Francisco García-Gutiérrez, María S. Gasparyan, Ani Navarro, Daniela Manzanares, Jorge Biomolecules Review The pharmacological modulation of the cannabinoid receptor 2 (CB2r) has emerged as a promising potential therapeutic option in addiction. The purpose of this review was to determine the functional involvement of CB2r in the effects produced by drugs of abuse at the central nervous system (CNS) level by assessing evidence from preclinical and clinical studies. In rodents, several reports suggest the functional involvement of CB2r in the effects produced by drugs of abuse such as alcohol, cocaine, or nicotine. In addition, the discovery of CB2r in brain areas that are part of the reward system supports the relevance of CB2r in the field of addiction. Interestingly, animal studies support that the CB2r regulates anxiety and depression behavioral traits. Due to its frequent comorbidity with neuropsychiatric disorders, these pharmacological actions may be of great interest in managing SUD. Preliminary clinical trials are focused on exploring the therapeutic potential of modulating CB2r in treating addictive disorders. These promising results support the development of new pharmacological tools regulating the CB2r that may help to increase the therapeutic success in the management of SUD. MDPI 2021-10-20 /pmc/articles/PMC8615453/ /pubmed/34827554 http://dx.doi.org/10.3390/biom11111556 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Navarrete, Francisco
García-Gutiérrez, María S.
Gasparyan, Ani
Navarro, Daniela
Manzanares, Jorge
CB2 Receptor Involvement in the Treatment of Substance Use Disorders
title CB2 Receptor Involvement in the Treatment of Substance Use Disorders
title_full CB2 Receptor Involvement in the Treatment of Substance Use Disorders
title_fullStr CB2 Receptor Involvement in the Treatment of Substance Use Disorders
title_full_unstemmed CB2 Receptor Involvement in the Treatment of Substance Use Disorders
title_short CB2 Receptor Involvement in the Treatment of Substance Use Disorders
title_sort cb2 receptor involvement in the treatment of substance use disorders
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8615453/
https://www.ncbi.nlm.nih.gov/pubmed/34827554
http://dx.doi.org/10.3390/biom11111556
work_keys_str_mv AT navarretefrancisco cb2receptorinvolvementinthetreatmentofsubstanceusedisorders
AT garciagutierrezmarias cb2receptorinvolvementinthetreatmentofsubstanceusedisorders
AT gasparyanani cb2receptorinvolvementinthetreatmentofsubstanceusedisorders
AT navarrodaniela cb2receptorinvolvementinthetreatmentofsubstanceusedisorders
AT manzanaresjorge cb2receptorinvolvementinthetreatmentofsubstanceusedisorders